Mozart Therapeutics
Brent Meengs is a seasoned scientist with extensive experience in the biotechnology and pharmaceuticals sectors. Currently serving as a Senior Scientist at Mozart Therapeutics, Inc. since December 2021, Brent previously held the position of Development Scientist at AGC Biologics from January 2020 to December 2021. Prior to that, Brent worked as the Formulation Development Manager at the Infectious Disease Research Institute from May 2019 to January 2020. Brent's career began at ZymoGenetics (Bristol-Myers Squibb), where roles included Scientist II and Scientist I from June 2014 to December 2018, as well as various positions from Associate Scientist to Research Associate III from 2000 to June 2014. Brent's early career included a stint as a Research Associate at Cell Therapeutics from 1992 to 1999. Brent holds a Bachelor of Arts degree in Biology from Whitman College.
Mozart Therapeutics
Mozart Therapeutics is a biotech startup focusing on the development of disease-modifying therapies for autoimmune and inflammatory diseases. The company is using a novel regulatory CD8 T cell network to create disease-modifying CD8 Treg modulators for a variety of autoimmune diseases. Mozart is developing a pipeline of first-in-class 'CD8Treg modulators with the goal of restoring long-term immune balance and preventing the progressive damage caused by an autoreactive and pathogenic immune response.